Shattuck Labs (STTK) to Release Earnings on Thursday

Shattuck Labs (NASDAQ:STTK) is expected to issue its Q4 2024 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.29) per share for the quarter.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.01. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 61.92%. On average, analysts expect Shattuck Labs to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shattuck Labs Stock Down 4.7 %

Shares of NASDAQ:STTK opened at $0.85 on Thursday. Shattuck Labs has a fifty-two week low of $0.69 and a fifty-two week high of $11.76. The firm’s 50-day simple moving average is $1.12 and its 200-day simple moving average is $1.18. The company has a market cap of $40.78 million, a price-to-earnings ratio of -0.56 and a beta of 1.76.

Analyst Upgrades and Downgrades

Several research firms have issued reports on STTK. Leerink Partnrs upgraded Shattuck Labs to a “strong-buy” rating in a research report on Monday, March 17th. Needham & Company LLC reiterated a “hold” rating on shares of Shattuck Labs in a research report on Thursday, March 27th. HC Wainwright restated a “neutral” rating on shares of Shattuck Labs in a research report on Thursday, March 27th. Finally, Leerink Partners began coverage on shares of Shattuck Labs in a report on Monday, March 17th. They issued an “outperform” rating and a $4.00 price target for the company. Four analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $7.50.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.